|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 当量比和反应物混合模式对无焰燃烧的影响显示文摘给出空气和燃料在3种初始混合模式(非预混、部分预混和完全预混)下无焰燃烧的实验结果,介绍了无焰燃烧的实现方法,研究当量比和初始混合模式对无焰燃烧的影响。实验炉在功率为7.5~15 kW下运行,当量比的变化范围为0.5~1。实验结果表明,无焰燃烧状态一旦建立则很稳定,很容易维持。无论是预混、非预混还是部分预混燃烧,其炉温差别不大,CO和NOx排放低。当量比接近1时,虽然炉内仍处于无焰燃烧状态且NOx排放量少,但CO和H2排放量都极多,此时并不是清洁燃烧。当量比小于0.98时,3种混合模式下烟气中的CO和H2含量都极低,但部分预混无焰燃烧产生的NOx排放量相对较多,而完全预混无焰燃烧的NOx排放量最低。文中还对当量比对NOx排放量的影响进行了详细分析。 | 李鹏飞 米建春 Bassam B.Dally Richard A.Craig 王飞飞 | 2011 | 中国电机工程学报2011，31，5： | 18 |
| 2 | Event studies in economics and finance显示文摘 | A.Craig Mackinlay | | 0，，： | 1 |
| 3 | General Education and the Coursein Argumentation显示文摘 | Baird A.Craig | | 0，，30： | 1 |
| 4 | Sectoral Solow residuals显示文摘 | A.Craig Burnside Martin S. Eichenbaum Sergio T. Rebelo | 1996 | European Economic Review1996，，3： | 1 |
| 5 | 结直肠癌的免疫调控点和免疫治疗显示文摘尽管过去10年间结直肠癌在早期诊断水平和总体生存改善方面有着稳步提高,但其仍是世界范围内主要致死疾病之一。目前包括化疗和生物治疗在内的治疗模式似乎已经达到了一个很高的高度,然而,免疫治疗尤其是免疫调控点抑制剂,也已在包括错配修复缺失的结直肠癌在内的多种癌症治疗中显示出良好的临床效果。由此萌发出一些针对免疫治疗新药进行评估(包括单药、多药、与化疗联合应用)的临床试验的设计与实施。本文对这些免疫调控抑制剂的生物学特性和临床前数据进行了综述,并对多项结直肠癌免疫治疗相关的临床试验和目前结直肠癌免疫治疗的努力方向进行了讨论。 | Preet Paul Singh Piyush K.Sharma Gayathri Krishnan A.Craig Lockhart | 2015 | Gastroenterology Report2015，3，4： | 0 |
| 6 | Molecular pathology of thymoma and thymic carcinoma显示文摘Thymic epithelial tumors(TETs)comprise a heterogeneous group of epithelial-derived thymic neoplasms with diverse clinical behavior and underlying molecular genetic features.Owing to their rare nature,the molecular classification of TETs has only recently begun to be fully explored.The advent of advanced molecular studies,particularly the ability to sequence the DNA and RNA of tumors in a massively parallel fashion,has led to an increased understanding of the molecular underpinnings of thymic neoplasia.Thymomas,characterized by a heterogeneous group of molecular alterations,tend to have low mutational burdens and various copy number abnormalities including a characteristic loss of chromosomal material in the region of 6q25.2-p25.3,a recurrent,specific point mutation GTF2I p.L424H,and specific expression of certain microRNAs.Thymic carcinomas,in contrast,are generally characterized by increased tumor mutational burdens,multiple copy number alterations,and varied,non-recurrent,somatic mutations.Advances in molecular knowledge of TETs allow for more precise molecular classification of these tumors,and the presence of specific alterations aids in the diagnosis of borderline lesions.In the future,additional molecular studies will better delineate the molecular landscape of these tumors and may one day allow for more targeted treatment algorithms.This review aims to cover the current understanding of the molecular alterations thus far identified in thymomas and thymic carcinomas. | David I.Suster Malay Kumar Basu A.Craig Mackinnon | 2022 | Journal of Cancer Metastasis and Treatment2022，8，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员